# Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

> **NCT02293850** · PHASE1 · UNKNOWN · sponsor: **Oncolys BioPharma Inc** · enrollment: 18 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **BIOLOGICAL:** OBP-301

## Key facts

- **NCT ID:** NCT02293850
- **Lead sponsor:** Oncolys BioPharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2019-04
- **Final completion:** 2021-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02293850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02293850, "Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02293850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*